Manufacturing roundup: Symbiosis, BioGrad, Abzena, Eschbach and more
This update includes sterile manufacturing, bio-manufacturing, cell line development and radiopharmaceuticals.
List view / Grid view
News
Takeda withdraws from clinical cell therapy activities
The company will instead focus its attention on advancing candidates for modalities that include biologics and ADCs.
AI adoption in life science labs faces a growing skills barrier
Pistoia Alliance survey also found that the greatest benefit for lab digitalisation has shifted from efficiency to innovation.
Teva closes in on sale of API business TAPI
The pharma company’s plan to divest its active pharmaceutical ingredient interests was first announced in 2024.
Bassem Saleh joins Netherlands CRO Julius Clinical as its new CEO
He arrives at the Netherlands-based contract research organisation from TFS HealthScience.
Call for greater investment and innovation from pharma to address RSV
Despite progress from AstraZeneca, Sanofi, Merck & Co, GSK and Pfizer, analysts say effective respiratory syncytial virus treatments are still needed.
Polpharma Biologics splits into biosimilars and CDMO businesses
Contract development and manufacturing services will be provided as Rezon Bio from Poland, with the biosimilars company operating from Switzerland.
J&J’s Tremfya secures two paediatric psoriasis approvals from FDA
The US FDA approvals make the drug the first IL-23 inhibitor to be licensed for two common skin conditions.
Kai Beckmann to take over from Belén Garijo as Merck CEO
The planned succession will also see him become Chair of the German pharma company’s Executive Board in May 2026.
Genmab makes $8bn acquisition to boost late-stage antibody therapy pipeline
The deal will support the biotech in its plans to advance bispecific antibody petosemtamab in multiple oncology indications.
GSK’s Emma Walmsley to step down as CEO
In a surprise announcement, she will be replaced at the UK pharma company by its Chief Commercial Officer Luke Miels.
Lilly wins European Alzheimer’s approval for Kisunla after regulatory setbacks
The anti-amyloid monoclonal antibody is part of the class of medicines representing the first disease-modifying therapies for the neurodegenerative disease.
Trump upends drug import policy with 100 percent tariff threat
Pharma manufacturing facility construction placed at the heart of a policy announcement made on social media.
Moderna opens UK’s first mRNA vaccine manufacturing facility
As other pharma companies reconsider their investments, Moderna’s focus insulates it from the UK’s drug pricing row.
One-time gene therapy could “transform” Huntington’s treatment landscape
uniQure’s positive topline data “are the most convincing in the field to date” and indicate the gene therapy’s potential disease-modifying effects.
